Search Results - "British journal of dermatology (1951)"

Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility by Has, C., Bauer, J.W., Bodemer, C., Bolling, M.C., Bruckner‐Tuderman, L., Diem, A., Fine, J.‐D., Heagerty, A., Hovnanian, A., Marinkovich, M.P., Martinez, A.E., McGrath, J.A., Moss, C., Murrell, D.F., Palisson, F., Schwieger‐Briel, A., Sprecher, E., Tamai, K., Uitto, J., Woodley, D.T., Zambruno, G., Mellerio, J.E.

“…Summary Background Several new genes and clinical subtypes have been identified since the publication in 2014 of the report of the last International Consensus…”
Get full text

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials by Simpson, E.L., Lacour, J.‐P., Spelman, L., Galimberti, R., Eichenfield, L.F., Bissonnette, R., King, B.A., Thyssen, J.P., Silverberg, J.I., Bieber, T., Kabashima, K., Tsunemi, Y., Costanzo, A., Guttman‐Yassky, E., Beck, L.A., Janes, J.M., DeLozier, A.M., Gamalo, M., Brinker, D.R., Cardillo, T., Nunes, F.P., Paller, A.S., Wollenberg, A., Reich, K.

“…Summary Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with…”
Get full text

Conjunctivitis in dupilumab clinical trials by Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.

“…Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years…”
Get full text

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) by Bruin‐Weller, M., Thaçi, D., Smith, C.H., Reich, K., Cork, M.J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., Hultsch, T., Chen, Z., Pirozzi, G., Graham, N.M.H., Shumel, B.

“…Summary Background Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent…”
Get full text

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity by Zouboulis, C.C., Tzellos, T., Kyrgidis, A., Jemec, G.B.E., Bechara, F.G., Giamarellos‐Bourboulis, E.J., Ingram, J.R., Kanni, T., Karagiannidis, I., Martorell, A., Matusiak, Ł., Pinter, A., Prens, E.P., Presser, D., Schneider‐Burrus, S., von Stebut, E., Szepietowski, J.C., Zee, H.H., Wilden, S.M., Sabat, R., Sinclair, R., Vekic, D., Haes, P., Marmol, V., Alavi, A., Gulliver, W., Nassif, A., Nikolakis, G., Podda, M., Antoniou, C., Delli, F.S., Dessinioti, C., Patsatsi, A., Trigoni, A.P., Zisimou, C., Bettoli, V., Garcovich, S., Boer, J., Horváth, B., Ingvarsson, G., Puig, L., Hunger, R.E., Emtestam, L., Danby, F.W., Kimball, A.B.

“…Summary Background A validated tool for the dynamic severity assessment of hidradenitis suppurativa/acne inversa (HS) is lacking. Objectives To develop and…”
Get full text

Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue by Marzano, A.V., Cassano, N., Genovese, G., Moltrasio, C., Vena, G.A.

“…Summary Background The infection caused by the recently identified SARS‐CoV‐2, called coronavirus disease‐19 (COVID‐19), has rapidly spread throughout the…”
Get full text

The global burden of melanoma: results from the Global Burden of Disease Study 2015 by Karimkhani, C., Green, A.C., Nijsten, T., Weinstock, M.A., Dellavalle, R.P., Naghavi, M., Fitzmaurice, C.

“…Summary Background Despite recent improvements in prevention, diagnosis and treatment, vast differences in melanoma burden still exist between populations…”
Get full text

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial by Bissonnette, R., Papp, K.A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., Ports, W.C.

“…Summary Background Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been…”
Get full text

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial by Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.

“…Summary Background Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of…”
Get full text

Gut microbiota dysbiosis in a cohort of patients with psoriasis by Hidalgo‐Cantabrana, C., Gómez, J., Delgado, S., Requena‐López, S., Queiro‐Silva, R., Margolles, A., Coto, E., Sánchez, B., Coto‐Segura, P.

“…Summary Background There is increasing evidence of the key role that the gut microbiota plays in inflammatory diseases. Objectives To identify differences in…”
Get full text

Deep‐learning‐based, computer‐aided classifier developed with a small dataset of clinical images surpasses board‐certified dermatologists in skin tumour diagnosis by Fujisawa, Y., Otomo, Y., Ogata, Y., Nakamura, Y., Fujita, R., Ishitsuka, Y., Watanabe, R., Okiyama, N., Ohara, K., Fujimoto, M.

“…Summary Background Application of deep‐learning technology to skin cancer classification can potentially improve the sensitivity and specificity of skin cancer…”
Get full text

Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis by Chopra, R., Vakharia, P.P., Sacotte, R., Patel, N., Immaneni, S., White, T., Kantor, R., Hsu, D.Y., Silverberg, J.I.

“…Summary Background Scoring systems for assessing the signs of atopic dermatitis (AD) are complex and difficult to interpret. Severity strata are helpful to…”
Get full text

Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management by Saunte, D.M., Mrowietz, U., Puig, L., Zachariae, C.

“…Summary The recognition of the central role of interleukin (IL)‐17A in the pathogenesis of psoriasis has led to the development of several monoclonal…”
Get full text

Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis by Totté, J.E.E., van der Feltz, W.T., Hennekam, M., van Belkum, A., van Zuuren, E.J., Pasmans, S.G.M.A.

“…Summary Background Staphylococcus aureus is increasingly implicated as a possible causal factor in the pathogenesis of atopic dermatitis (AD). However, the…”
Get full text

Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel by Schaller, M., Almeida, L.M.C., Bewley, A., Cribier, B., Del Rosso, J., Dlova, N.C., Gallo, R.L., Granstein, R.D., Kautz, G., Mannis, M.J., Micali, G., Oon, H.H., Rajagopalan, M., Steinhoff, M., Tanghetti, E., Thiboutot, D., Troielli, P., Webster, G., Zierhut, M., Zuuren, E.J., Tan, J.

“…Summary Background A transition from a subtyping to a phenotyping approach in rosacea is underway, allowing individual patient management according to…”
Get full text

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study by Kardaun, S.H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C.Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., Roujeau, J.C.

“…Summary Background Cases of severe drug hypersensitivity, demonstrating a variable spectrum of cutaneous and systemic involvement, are reported under various…”
Get full text

Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non‐neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society by Errichetti, E., Zalaudek, I., Kittler, H., Apalla, Z., Argenziano, G., Bakos, R., Blum, A., Braun, R.P., Ioannides, D., Lacarrubba, F., Lazaridou, E., Longo, C., Micali, G., Moscarella, E., Paoli, J., Papageorgiou, C., Russo, T., Scope, A., Stinco, G., Thomas, L., Toncic, R.J., Tschandl, P., Cabo, H., Hallpern, A., Hofmann‐Wellenhof, R., Malvehy, J., Marghoob, A., Menzies, S., Pellacani, G., Puig, S., Rabinovitz, H., Rudnicka, L., Vakirlis, E., Soyer, P., Stolz, W., Tanaka, M., Lallas, A.

“…Summary Background Over the last few years, several articles on dermoscopy of non‐neoplastic dermatoses have been published, yet there is poor consistency in…”
Get full text

Population‐based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa by Ingram, J.R., Jenkins‐Jones, S., Knipe, D.W., Morgan, C.L.I., Cannings‐John, R., Piguet, V.

“…Summary Background Epidemiology data regarding hidradenitis suppurativa (HS) are conflicting and prevalence estimates vary 80‐fold, from 0·05% in a…”
Get full text

Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study by Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., Sirna, R., Gisondi, P., Patrizi, A., Dini, V., Bianchini, D., Bianchi, L., Fania, L., Prignano, F., Offidani, A., Atzori, L., Bettoli, V., Cannavò, S.P., Venturini, M., Bongiorno, M. R., Costanzo, A., Fabbrocini, G., Peris, K.

“…Summary Background The anti‐tumour necrosis factor (TNF)‐α adalimumab is the only licenced biologic for moderate‐to‐severe hidradenitis suppurativa (HS). No…”
Get full text

Diagnostic delay in hidradenitis suppurativa is a global problem by Saunte, D.M., Boer, J., Stratigos, A., Szepietowski, J.C., Hamzavi, I., Kim, K.H., Zarchi, K., Antoniou, C., Matusiak, L., Lim, H.W., Williams, M., Kwon, H.H., Gürer, M.A., Mammadova, F., Kaminsky, A., Prens, E., van der Zee, H.H., Bettoli, V., Zauli, S., Hafner, J., Lauchli, S., French, L.E., Riad, H., El-Domyati, M., Abdel-Wahab, H., Kirby, B., Kelly, G., Calderon, P., del Marmol, V., Benhadou, F., Revuz, J., Zouboulis, C.C., Karagiannidis, I., Sartorius, K., Hagströmer, L., McMeniman, E., Ong, N., Dolenc-Voljc, M., Mokos, Z.B., Borradori, L., Hunger, R.E., Sladden, C., Scheinfeld, N., Moftah, N., Emtestam, L., Lapins, J., Doss, N., Kurokawa, I., Jemec, G.B.E.

“…Plain language summary available online…”
Get full text